Hello everyone! I hope all of you had a wonderful weekend. Lets start our busy week ahead with some Best 5 Reads on Mental Health!
Recently, someone posted the following on Instagram: “I am clinically #bipolar, which means that I don’t know what my mood will be like in the next 20 minutes.” This sparked some discussion among doctors on Twitter, who noted, correctly, that mood episodes in bipolar disorder last days to weeks, not minutes or hours.
The Instagram post and Twitter discussion also sparked discussion among people who live with bipolar disorder, which made me think that an expanded conversation would be helpful.
In this post, I highlight the distinctions between moodiness and bipolar disorder, and explain why these distinctions matter.
I DISCOVERED CrazySocks4Docs Day – held annually on 1 June – only this year. The day aims to “encourage conversations about mental health and help reduce the stigma for doctors experiencing mental illness”. When I discovered the day thanks to my burgeoning Twitter obsession, I experienced an incredible and overwhelming reaction.
Almost exactly 30 years before, as an intern in the central Queensland city of Rockhampton, I had tried to kill myself. Three decades later, I am now President of a specialist college, but I had kept the entire episode to myself and tried to forget it. I am deeply ashamed of not learning from my own experience and using it to help others.
I hope it isn’t too late.
Tardive dyskinesia, an involuntary athetoid or choreiform movements, generally of the tongue, lower face and jaw, and extremities, is highly prevalent in patients with schizophrenia after long-term antipsychotic use. What about clozapine for TD?
Currently, considerable effort is devoted to finding novel drug targets. Problematically, the development of new medications is extremely expensive and takes many years. A parallel and potentially more immediate route to enhance treatment efficacy and minimize common adverse effects is to tailor the use of existing drugs to individual patients. However, the field of precision medicine has struggled to develop accurate approaches for predicting psychotropic drug response. Initial efforts involved pharmacogenetic studies of candidate genes thought to be relevant to the pharmacokinetics and pharmacodynamics of the drug. These studies were hampered by the fact that deep mechanistic knowledge of drug action is typically lacking. With advances in genomic technologies, it has become possible to bypass the need for such knowledge by studying genetic variation on a genome-wide scale. This has yielded multiple encouraging findings.
The researchers noted that counties should consider increasing funding for mobile crisis teams staffed by professionals who can direct patients to medical emergency departments or psychiatric emergency service units depending on their evaluation.
Thank you and see you tomorrow for more articles.